A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab

Immunotherapy is an effective new approach in the treatment of many malignancies. However, pancreatic ductal adenocarcinoma (PDAC) does not usually respond to immunotherapy. We discuss the case of a patient with metastatic microsatellite instability-high PDAC who had a prolonged response to single-a...

Full description

Bibliographic Details
Main Authors:	Annie A. Guedikian, Megan E. Randall, Anita Sharko, William T. Leslie
Format:	Article
Language:	English
Published:	Karger Publishers 2021-09-01
Series:	Case Reports in Oncology
Subjects:	metastatic pancreatic ductal adenocarcinoma mismatch repair deficiency microsatellite instability programmed cell death protein 1 inhibitor
Online Access:	https://www.karger.com/Article/FullText/519181

id	doaj-7d8b3d830cc5499cbe1d87105c2e5414
record_format	Article
spelling	doaj-7d8b3d830cc5499cbe1d87105c2e54142021-10-07T13:44:28ZengKarger PublishersCase Reports in Oncology1662-65752021-09-011431414141710.1159/000519181519181A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent PembrolizumabAnnie A. Guedikianhttps://orcid.org/0000-0002-9578-6514Megan E. RandallAnita SharkoWilliam T. LeslieImmunotherapy is an effective new approach in the treatment of many malignancies. However, pancreatic ductal adenocarcinoma (PDAC) does not usually respond to immunotherapy. We discuss the case of a patient with metastatic microsatellite instability-high PDAC who had a prolonged response to single-agent pembrolizumab for almost 3 years.https://www.karger.com/Article/FullText/519181metastatic pancreatic ductal adenocarcinomamismatch repair deficiencymicrosatellite instabilityprogrammed cell death protein 1 inhibitor
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Annie A. Guedikian Megan E. Randall Anita Sharko William T. Leslie
spellingShingle	Annie A. Guedikian Megan E. Randall Anita Sharko William T. Leslie A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab Case Reports in Oncology metastatic pancreatic ductal adenocarcinoma mismatch repair deficiency microsatellite instability programmed cell death protein 1 inhibitor
author_facet	Annie A. Guedikian Megan E. Randall Anita Sharko William T. Leslie
author_sort	Annie A. Guedikian
title	A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab
title_short	A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab
title_full	A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab
title_fullStr	A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab
title_full_unstemmed	A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab
title_sort	patient with metastatic microsatellite instability-high pancreatic ductal adenocarcinoma with a prolonged response to single-agent pembrolizumab
publisher	Karger Publishers
series	Case Reports in Oncology
issn	1662-6575
publishDate	2021-09-01
description	Immunotherapy is an effective new approach in the treatment of many malignancies. However, pancreatic ductal adenocarcinoma (PDAC) does not usually respond to immunotherapy. We discuss the case of a patient with metastatic microsatellite instability-high PDAC who had a prolonged response to single-agent pembrolizumab for almost 3 years.
topic	metastatic pancreatic ductal adenocarcinoma mismatch repair deficiency microsatellite instability programmed cell death protein 1 inhibitor
url	https://www.karger.com/Article/FullText/519181
work_keys_str_mv	AT annieaguedikian apatientwithmetastaticmicrosatelliteinstabilityhighpancreaticductaladenocarcinomawithaprolongedresponsetosingleagentpembrolizumab AT meganerandall apatientwithmetastaticmicrosatelliteinstabilityhighpancreaticductaladenocarcinomawithaprolongedresponsetosingleagentpembrolizumab AT anitasharko apatientwithmetastaticmicrosatelliteinstabilityhighpancreaticductaladenocarcinomawithaprolongedresponsetosingleagentpembrolizumab AT williamtleslie apatientwithmetastaticmicrosatelliteinstabilityhighpancreaticductaladenocarcinomawithaprolongedresponsetosingleagentpembrolizumab AT annieaguedikian patientwithmetastaticmicrosatelliteinstabilityhighpancreaticductaladenocarcinomawithaprolongedresponsetosingleagentpembrolizumab AT meganerandall patientwithmetastaticmicrosatelliteinstabilityhighpancreaticductaladenocarcinomawithaprolongedresponsetosingleagentpembrolizumab AT anitasharko patientwithmetastaticmicrosatelliteinstabilityhighpancreaticductaladenocarcinomawithaprolongedresponsetosingleagentpembrolizumab AT williamtleslie patientwithmetastaticmicrosatelliteinstabilityhighpancreaticductaladenocarcinomawithaprolongedresponsetosingleagentpembrolizumab
_version_	1716839329379123200

A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab

Similar Items